Friday, 04 December 2020

Neeraj Bhargava joins MedGenome Board of Directors

12 March 2019 | News

Neeraj has a stellar career behind him that includes taking companies from launch to unicorn status.

MedGenome, a genomics and clinical data driven diagnostics and drug discovery research company, announced that Neeraj Bhargava has joined their Board of Directors.

Neeraj, an alumnus of St. Stephens, Delhi, is the founder, CEO and Senior Managing Director of Zodius Capital Advisors. Zodius is an early investor in MedGenome. Neeraj is passionate about building market-defining companies across industries that challenge the status-quo.

Neeraj has a stellar career behind him that includes taking companies from launch to unicorn status. Prior to joining Zodius, he had co-founded and led multiple companies including WNS Global Services and eVentures India. Currently, Neeraj is an investor-operator and a board member at companies like BigBasket, Allygrow and Markets & Markets. Neeraj is also the CEO and Chairman of Rainshine Entertainment, a next-generation media and entertainment company.

“Neeraj’s unique combination of entrepreneurial, consulting and operational experience, coupled with his unparalleled network across the globe, makes him an ideal mentor for MedGenome” said Sam Santhosh Founder and Chairman of MedGenome. “Genomics is set to redefine the way healthcare is accessed and delivered today. We look forward to Neeraj’s guidance as we embark on the next phase of our growth. ”

“Genomics is an industry of the future and MedGenome is already a leader in the field. I am most impressed by MedGenome’s team and their scientific approach.  I look forward to working closely with them to drive their next phase of growth,” said Neeraj Bhargava.

Earlier in his career, Neeraj was a partner at McKinsey & Company, where he worked at New York, London and Mumbai offices and led practices and client relationships in the technology sector.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls